NASDAQ:ALKS
Alkermes plc Stock News
$24.26
+0.160 (+0.664%)
At Close: May 09, 2024
Macquarie Group Ltd. Grows Position in Alkermes Plc (NASDAQ:ALKS)
10:24am, Tuesday, 07'th Apr 2020
Macquarie Group Ltd. grew its position in shares of Alkermes Plc (NASDAQ:ALKS) by 4.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The
Alkermes clinical lead jumps ship to slimmed-down, refocused Seres
11:52am, Monday, 06'th Apr 2020
After axing its chief scientific officer last year amid a raft of changes to its C-suite and beyond, Seres Therapeutics has nabbed a new chief medical officer from Alkermes.
Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer
11:00am, Monday, 06'th Apr 2020
Dr. Lisa von Moltke joins as CMO of Seres with an extensive career that includes senior leadership positions at Alkermes and Sanofi Genzyme.
Richard F. Pops Sells 50,000 Shares of Alkermes Plc (NASDAQ:ALKS) Stock
08:46am, Sunday, 05'th Apr 2020
Alkermes Plc (NASDAQ:ALKS) CEO Richard F. Pops sold 50,000 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $13.79, for a total t
Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?
02:02pm, Saturday, 04'th Apr 2020
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Alkermes Plc (NASDAQ:ALKS) Expected to Announce Quarterly Sales of $224.97 Million
08:32am, Saturday, 04'th Apr 2020
Brokerages expect Alkermes Plc (NASDAQ:ALKS) to post $224.97 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Alkermes’ e
BRIEF-Alkermes Says Total Compensation For CEO Richard Pops Was $14.6 Mln In 2019 Versus $17.1 Mln In 2018
09:54pm, Friday, 03'rd Apr 2020
Alkermes Plc:
Alkermes Plc (ALKS) Director and CEO, Alkermes plc Richard F Pops Sold $689,5…… of Shares
12:00am, Friday, 03'rd Apr 2020Alkermes (ALKS) Gets a Hold Rating from Morgan Stanley
05:30pm, Thursday, 02'nd Apr 2020
Morgan Stanley analyst David Risinger maintained a Hold rating on Alkermes (ALKS) today and set a price target of $16.00. The company's shares closed last
Morgan Stanley Maintains Equal-Weight on Alkermes, Lowers Price Target to $16
12:00am, Thursday, 02'nd Apr 2020Connor Clark & Lunn Investment Management Ltd. Grows Stake in Alkermes Plc (NASDAQ:ALKS)
10:02am, Wednesday, 01'st Apr 2020
Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Alkermes Plc (NASDAQ:ALKS) by 280.0% in the 4th quarter, according to its most recent disclosure with the Securities and Ex
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Marc de So
Amundi Pioneer Asset Management Inc. Sells 60,966 Shares of Alkermes Plc (NASDAQ:ALKS)
08:52am, Tuesday, 31'st Mar 2020
Amundi Pioneer Asset Management Inc. lowered its position in Alkermes Plc (NASDAQ:ALKS) by 80.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission
Alkermes Plc (NASDAQ:ALKS) Sees Large Growth in Short Interest
05:10am, Tuesday, 31'st Mar 2020
Alkermes Plc (NASDAQ:ALKS) was the target of a large growth in short interest during the month of March. As of March 13th, there was short interest totalling 6,459,600 shares, a growth of 12.7% from t
Valmont Industries, Inc. (VMI): Are Hedge Funds Right About This Stock?
02:25am, Monday, 30'th Mar 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
